Methallenestril

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Methallenestril
Accession Number
DB13143
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
  • b-ethyl-6-methoxy-a,a-dimethyl-2-naphthalenepropionic acid
International/Other Brands
Vallestril
Categories
UNII
XL025389JS
CAS number
517-18-0
Weight
Average: 286.371
Monoisotopic: 286.156894568
Chemical Formula
C18H22O3
InChI Key
KHLJKRBMZVNZOC-MRXNPFEDSA-N
InChI
InChI=1S/C18H22O3/c1-5-16(18(2,3)17(19)20)14-7-6-13-11-15(21-4)9-8-12(13)10-14/h6-11,16H,5H2,1-4H3,(H,19,20)/t16-/m1/s1
IUPAC Name
(3R)-3-(6-methoxynaphthalen-2-yl)-2,2-dimethylpentanoic acid
SMILES
CC[[email protected]](C1=CC=C2C=C(OC)C=CC2=C1)C(C)(C)C(O)=O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Methallenestril can be decreased when it is combined with 1,10-Phenanthroline.Experimental
16-BromoepiandrosteroneThe serum concentration of 16-Bromoepiandrosterone can be increased when it is combined with Methallenestril.Investigational
19-norandrostenedioneThe serum concentration of 19-norandrostenedione can be increased when it is combined with Methallenestril.Experimental, Illicit
3,4-DichloroisocoumarinThe serum concentration of Methallenestril can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Methallenestril can be decreased when it is combined with 4-(2-Aminoethyl)Benzenesulfonyl Fluoride.Experimental
5-androstenedioneThe serum concentration of 5-androstenedione can be increased when it is combined with Methallenestril.Experimental, Illicit
AbciximabMethallenestril may decrease the anticoagulant activities of Abciximab.Approved
AcenocoumarolMethallenestril may decrease the anticoagulant activities of Acenocoumarol.Approved
AcitretinThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Acitretin.Approved
AdapaleneThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Adapalene.Approved
AlclometasoneThe serum concentration of Alclometasone can be increased when it is combined with Methallenestril.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Methallenestril.Experimental, Investigational
AlitretinoinThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Methallenestril can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Methallenestril can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
Ambroxol acefyllinateThe serum concentration of Ambroxol acefyllinate can be increased when it is combined with Methallenestril.Experimental, Investigational
AmcinonideThe serum concentration of Amcinonide can be increased when it is combined with Methallenestril.Approved
AmobarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Amobarbital.Approved, Illicit
AmprenavirThe serum concentration of Methallenestril can be decreased when it is combined with Amprenavir.Approved
AnastrozoleThe therapeutic efficacy of Anastrozole can be decreased when used in combination with Methallenestril.Approved, Investigational
AncrodMethallenestril may decrease the anticoagulant activities of Ancrod.Investigational
AndrostenedioneThe serum concentration of Androstenedione can be increased when it is combined with Methallenestril.Experimental, Illicit
AnecortaveThe serum concentration of Anecortave can be increased when it is combined with Methallenestril.Investigational
anecortave acetateThe serum concentration of anecortave acetate can be increased when it is combined with Methallenestril.Investigational
Anthrax immune globulin humanMethallenestril may increase the thrombogenic activities of Anthrax immune globulin human.Approved
Antithrombin III humanThe serum concentration of Methallenestril can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Methallenestril can be decreased when it is combined with Apixaban.Approved
AprepitantThe serum concentration of Methallenestril can be decreased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Methallenestril can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArdeparinMethallenestril may decrease the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanThe serum concentration of Methallenestril can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Methallenestril can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Methallenestril can be decreased when it is combined with Artemether.Approved
AsunaprevirThe serum concentration of Methallenestril can be decreased when it is combined with Asunaprevir.Approved, Investigational
AtamestaneThe serum concentration of Atamestane can be increased when it is combined with Methallenestril.Investigational
AtazanavirThe serum concentration of Methallenestril can be decreased when it is combined with Atazanavir.Approved, Investigational
BarbexacloneThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Barbital.Illicit
BatimastatThe serum concentration of Methallenestril can be decreased when it is combined with Batimastat.Experimental
BecaplerminMethallenestril may decrease the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe serum concentration of Beclomethasone dipropionate can be increased when it is combined with Methallenestril.Approved, Investigational
BenazeprilThe serum concentration of Methallenestril can be decreased when it is combined with Benazepril.Approved, Investigational
BenzamidineThe serum concentration of Methallenestril can be decreased when it is combined with Benzamidine.Experimental
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Methallenestril.Approved, Vet Approved
BexaroteneThe serum concentration of Methallenestril can be decreased when it is combined with Bexarotene.Approved, Investigational
BivalirudinThe serum concentration of Methallenestril can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Methallenestril can be decreased when it is combined with Boceprevir.Approved, Withdrawn
BosentanThe serum concentration of Methallenestril can be decreased when it is combined with Bosentan.Approved, Investigational
BudesonideThe serum concentration of Budesonide can be increased when it is combined with Methallenestril.Approved
CamostatThe serum concentration of Methallenestril can be decreased when it is combined with Camostat.Experimental
CandoxatrilThe serum concentration of Methallenestril can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Methallenestril can be decreased when it is combined with Candoxatrilat.Experimental
Capromab pendetideMethallenestril may decrease effectiveness of Capromab pendetide as a diagnostic agent.Approved
CaptoprilThe serum concentration of Methallenestril can be decreased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Carbamazepine.Approved, Investigational
CelecoxibCelecoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational
CertoparinMethallenestril may decrease the anticoagulant activities of Certoparin.Approved, Investigational
Chenodeoxycholic acidThe therapeutic efficacy of Chenodeoxycholic acid can be decreased when used in combination with Methallenestril.Approved
CholesterolThe serum concentration of Methallenestril can be decreased when it is combined with Cholesterol.Experimental, Investigational
CholestyramineThe serum concentration of Methallenestril can be decreased when it is combined with Cholestyramine.Approved
ChymostatinThe serum concentration of Methallenestril can be decreased when it is combined with Chymostatin.Experimental
CiclesonideThe serum concentration of Ciclesonide can be increased when it is combined with Methallenestril.Approved, Investigational
CilastatinThe serum concentration of Methallenestril can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Methallenestril can be decreased when it is combined with Cilazapril.Approved
Citric AcidMethallenestril may decrease the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobazamThe serum concentration of Methallenestril can be decreased when it is combined with Clobazam.Approved, Illicit
ClobetasolThe serum concentration of Clobetasol can be increased when it is combined with Methallenestril.Investigational
Clobetasol propionateThe serum concentration of Clobetasol propionate can be increased when it is combined with Methallenestril.Approved
ClobetasoneThe serum concentration of Clobetasone can be increased when it is combined with Methallenestril.Approved
ClocortoloneThe serum concentration of Clocortolone can be increased when it is combined with Methallenestril.Approved
ClorindioneMethallenestril may decrease the anticoagulant activities of Clorindione.Experimental
CobicistatThe serum concentration of Methallenestril can be decreased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Methallenestril can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Methallenestril can be decreased when it is combined with Colestipol.Approved
Cortexolone 17α-propionateThe serum concentration of Cortexolone 17α-propionate can be increased when it is combined with Methallenestril.Investigational
CorticosteroneThe serum concentration of Corticosterone can be increased when it is combined with Methallenestril.Experimental
Cortisone acetateThe serum concentration of Cortisone acetate can be increased when it is combined with Methallenestril.Approved
Dabigatran etexilateThe serum concentration of Methallenestril can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Methallenestril can be decreased when it is combined with Dabrafenib.Approved
DalteparinMethallenestril may decrease the anticoagulant activities of Dalteparin.Approved
DanaparoidMethallenestril may decrease the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanThe serum concentration of Methallenestril can be decreased when it is combined with Darexaban.Investigational
DarunavirThe serum concentration of Methallenestril can be decreased when it is combined with Darunavir.Approved
DeflazacortThe serum concentration of Deflazacort can be increased when it is combined with Methallenestril.Approved, Investigational
DelanzomibThe serum concentration of Methallenestril can be decreased when it is combined with Delanzomib.Investigational
DelaprilThe serum concentration of Methallenestril can be decreased when it is combined with Delapril.Experimental
DesirudinMethallenestril may decrease the anticoagulant activities of Desirudin.Approved
DesonideThe serum concentration of Desonide can be increased when it is combined with Methallenestril.Approved, Investigational
DesoximetasoneThe serum concentration of Desoximetasone can be increased when it is combined with Methallenestril.Approved
Desoxycorticosterone acetateThe serum concentration of Desoxycorticosterone acetate can be increased when it is combined with Methallenestril.Approved
Desoxycorticosterone PivalateThe serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Methallenestril.Experimental, Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Methallenestril.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe serum concentration of Dexamethasone isonicotinate can be increased when it is combined with Methallenestril.Vet Approved
DextranMethallenestril may decrease the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Methallenestril may decrease the anticoagulant activities of Dextran 40.Approved
Dextran 70Methallenestril may decrease the anticoagulant activities of Dextran 70.Approved
Dextran 75Methallenestril may decrease the anticoagulant activities of Dextran 75.Approved
DicoumarolMethallenestril may decrease the anticoagulant activities of Dicoumarol.Approved
DiflorasoneThe serum concentration of Diflorasone can be increased when it is combined with Methallenestril.Approved
DifluocortoloneThe serum concentration of Difluocortolone can be increased when it is combined with Methallenestril.Approved, Investigational, Withdrawn
DifluprednateThe serum concentration of Difluprednate can be increased when it is combined with Methallenestril.Approved
DiphenadioneMethallenestril may decrease the anticoagulant activities of Diphenadione.Experimental
EcabetThe serum concentration of Methallenestril can be decreased when it is combined with Ecabet.Approved, Investigational
Edetic AcidMethallenestril may decrease the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanThe serum concentration of Methallenestril can be decreased when it is combined with Edoxaban.Approved
ElafinThe serum concentration of Methallenestril can be decreased when it is combined with Elafin.Investigational
ElvitegravirThe serum concentration of Methallenestril can be decreased when it is combined with Elvitegravir.Approved
EnalaprilThe serum concentration of Methallenestril can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Methallenestril can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Methallenestril can be decreased when it is combined with Enalkiren.Experimental
EnoxaparinMethallenestril may decrease the anticoagulant activities of Enoxaparin.Approved
Epigallocatechin GallateThe serum concentration of Methallenestril can be decreased when it is combined with Epigallocatechin Gallate.Investigational
EquileninThe serum concentration of Equilenin can be increased when it is combined with Methallenestril.Experimental
EquilinThe serum concentration of Equilin can be increased when it is combined with Methallenestril.Approved
Eslicarbazepine acetateThe serum concentration of Methallenestril can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Methallenestril.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be increased when it is combined with Methallenestril.Approved
Ethyl biscoumacetateMethallenestril may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacEtodolac may increase the thrombogenic activities of Methallenestril.Approved, Investigational, Vet Approved
EtoricoxibEtoricoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational
ExemestaneThe therapeutic efficacy of Exemestane can be decreased when used in combination with Methallenestril.Approved, Investigational
ExenatideThe serum concentration of Methallenestril can be decreased when it is combined with Exenatide.Approved, Investigational
FaldaprevirThe serum concentration of Methallenestril can be decreased when it is combined with Faldaprevir.Investigational
FelbamateThe serum concentration of Methallenestril can be decreased when it is combined with Felbamate.Approved
Ferulic acidMethallenestril may decrease the anticoagulant activities of Ferulic acid.Experimental
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Methallenestril.Approved
FluasteroneThe serum concentration of Fluasterone can be increased when it is combined with Methallenestril.Investigational
FludrocortisoneThe serum concentration of Fludrocortisone can be increased when it is combined with Methallenestril.Approved
FluindioneMethallenestril may decrease the anticoagulant activities of Fluindione.Investigational
FlumethasoneThe serum concentration of Flumethasone can be increased when it is combined with Methallenestril.Approved, Vet Approved
FlunisolideThe serum concentration of Flunisolide can be increased when it is combined with Methallenestril.Approved, Investigational
Fluocinolone AcetonideThe serum concentration of Fluocinolone Acetonide can be increased when it is combined with Methallenestril.Approved, Investigational, Vet Approved
FluocinonideThe serum concentration of Fluocinonide can be increased when it is combined with Methallenestril.Approved, Investigational
FluocortoloneThe serum concentration of Fluocortolone can be increased when it is combined with Methallenestril.Approved, Withdrawn
FluorometholoneThe serum concentration of Fluorometholone can be increased when it is combined with Methallenestril.Approved
FluprednideneThe serum concentration of Fluprednidene can be increased when it is combined with Methallenestril.Approved, Withdrawn
FluprednisoloneThe serum concentration of Fluprednisolone can be increased when it is combined with Methallenestril.Approved
FlurandrenolideThe serum concentration of Flurandrenolide can be increased when it is combined with Methallenestril.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Methallenestril.Approved
Fluticasone propionateThe serum concentration of Fluticasone propionate can be increased when it is combined with Methallenestril.Approved
FondaparinuxMethallenestril may decrease the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumMethallenestril may decrease the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FormestaneThe serum concentration of Formestane can be increased when it is combined with Methallenestril.Approved, Investigational, Withdrawn
FosamprenavirThe serum concentration of Methallenestril can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Methallenestril can be decreased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Methallenestril can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Fosphenytoin.Approved
GabexateThe serum concentration of Methallenestril can be decreased when it is combined with Gabexate.Investigational
GeldanamycinThe serum concentration of Methallenestril can be decreased when it is combined with Geldanamycin.Experimental, Investigational
GM6001The serum concentration of Methallenestril can be decreased when it is combined with GM6001.Experimental
GriseofulvinThe metabolism of Methallenestril can be increased when combined with Griseofulvin.Approved, Vet Approved
HalcinonideThe serum concentration of Halcinonide can be increased when it is combined with Methallenestril.Approved, Investigational, Withdrawn
HE3286The serum concentration of HE3286 can be increased when it is combined with Methallenestril.Investigational
HeparinMethallenestril may decrease the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Hexobarbital.Approved
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Methallenestril.Approved, Investigational
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Methallenestril.Approved, Vet Approved
IdraparinuxThe serum concentration of Methallenestril can be decreased when it is combined with Idraparinux.Investigational
ImidaprilThe serum concentration of Methallenestril can be decreased when it is combined with Imidapril.Investigational
IndinavirThe serum concentration of Methallenestril can be decreased when it is combined with Indinavir.Approved
IsoflurophateThe serum concentration of Methallenestril can be decreased when it is combined with Isoflurophate.Approved, Investigational, Withdrawn
IsotretinoinThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Isotretinoin.Approved
IstaroximeThe serum concentration of Istaroxime can be increased when it is combined with Methallenestril.Investigational
IxazomibThe serum concentration of Methallenestril can be decreased when it is combined with Ixazomib.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Methallenestril.Approved, Investigational
LenalidomideMethallenestril may increase the thrombogenic activities of Lenalidomide.Approved
LepirudinThe serum concentration of Methallenestril can be decreased when it is combined with Lepirudin.Approved
LetaxabanThe serum concentration of Methallenestril can be decreased when it is combined with Letaxaban.Investigational
LinagliptinThe serum concentration of Methallenestril can be decreased when it is combined with Linagliptin.Approved
LisinoprilThe serum concentration of Methallenestril can be decreased when it is combined with Lisinopril.Approved, Investigational
LopinavirThe serum concentration of Methallenestril can be decreased when it is combined with Lopinavir.Approved
LoteprednolThe serum concentration of Loteprednol can be increased when it is combined with Methallenestril.Approved
LumacaftorThe serum concentration of Methallenestril can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibLumiracoxib may increase the thrombogenic activities of Methallenestril.Approved, Investigational
ME-609The serum concentration of ME-609 can be increased when it is combined with Methallenestril.Investigational
MedrysoneThe serum concentration of Medrysone can be increased when it is combined with Methallenestril.Approved
MelagatranThe serum concentration of Methallenestril can be decreased when it is combined with Melagatran.Experimental
MelengestrolThe serum concentration of Melengestrol can be increased when it is combined with Methallenestril.Vet Approved
MethohexitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Methohexital.Approved
MethylphenobarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Methylphenobarbital.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Methallenestril.Approved, Vet Approved
MetreleptinThe serum concentration of Methallenestril can be decreased when it is combined with Metreleptin.Approved
MifepristoneThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Mifepristone.Approved, Investigational
ModafinilThe serum concentration of Methallenestril can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Methallenestril can be decreased when it is combined with Moexipril.Approved
MometasoneThe serum concentration of Mometasone can be increased when it is combined with Methallenestril.Approved, Vet Approved
Mycophenolic acidThe serum concentration of Methallenestril can be decreased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Methallenestril can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneNabumetone may increase the thrombogenic activities of Methallenestril.Approved
NadroparinMethallenestril may decrease the anticoagulant activities of Nadroparin.Approved
NafamostatThe serum concentration of Methallenestril can be decreased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe metabolism of Methallenestril can be increased when combined with Nafcillin.Approved
NCX 1022The serum concentration of NCX 1022 can be increased when it is combined with Methallenestril.Investigational
NelfinavirThe serum concentration of Methallenestril can be decreased when it is combined with Nelfinavir.Approved
NevirapineThe serum concentration of Methallenestril can be decreased when it is combined with Nevirapine.Approved
NitroaspirinThe serum concentration of Methallenestril can be decreased when it is combined with Nitroaspirin.Investigational
Oleoyl-estroneThe serum concentration of Oleoyl-estrone can be increased when it is combined with Methallenestril.Investigational
OmapatrilatThe serum concentration of Methallenestril can be decreased when it is combined with Omapatrilat.Investigational
OspemifeneThe risk or severity of adverse effects can be increased when Methallenestril is combined with Ospemifene.Approved
OtamixabanThe serum concentration of Methallenestril can be decreased when it is combined with Otamixaban.Investigational
OxcarbazepineThe serum concentration of Methallenestril can be decreased when it is combined with Oxcarbazepine.Approved
ParamethasoneThe serum concentration of Paramethasone can be increased when it is combined with Methallenestril.Approved
ParecoxibParecoxib may increase the thrombogenic activities of Methallenestril.Approved
Pentaerythritol TetranitrateMethallenestril may decrease the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Pentobarbital.Approved, Vet Approved
Pentosan PolysulfateMethallenestril may decrease the anticoagulant activities of Pentosan Polysulfate.Approved
PerindoprilThe serum concentration of Methallenestril can be decreased when it is combined with Perindopril.Approved
PhenindioneMethallenestril may decrease the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Phenobarbital.Approved
PhenprocoumonMethallenestril may decrease the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenytoinThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Methallenestril can be decreased when it is combined with Phosphoramidon.Experimental
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Methallenestril.Approved, Nutraceutical
Prasterone sulfateThe serum concentration of Prasterone sulfate can be increased when it is combined with Methallenestril.Investigational
PrednicarbateThe serum concentration of Prednicarbate can be increased when it is combined with Methallenestril.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Methallenestril.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Methallenestril.Approved, Vet Approved
PregnenoloneThe serum concentration of Pregnenolone can be increased when it is combined with Methallenestril.Experimental, Investigational
PrimidoneThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Methallenestril can be decreased when it is combined with Prinomastat.Investigational
Protein CMethallenestril may decrease the anticoagulant activities of Protein C.Approved
Protein S humanMethallenestril may decrease the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMethallenestril may decrease the anticoagulant activities of Protocatechualdehyde.Approved
PrucaloprideThe serum concentration of Methallenestril can be decreased when it is combined with Prucalopride.Approved
QuinaprilThe serum concentration of Methallenestril can be decreased when it is combined with Quinapril.Approved, Investigational
RacecadotrilThe serum concentration of Methallenestril can be decreased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Methallenestril can be decreased when it is combined with Ramipril.Approved
RemikirenThe serum concentration of Methallenestril can be decreased when it is combined with Remikiren.Approved
ReviparinMethallenestril may decrease the anticoagulant activities of Reviparin.Approved, Investigational
RifabutinThe serum concentration of Methallenestril can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Methallenestril can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Methallenestril can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Methallenestril can be decreased when it is combined with Rifaximin.Approved, Investigational
RimexoloneThe serum concentration of Rimexolone can be increased when it is combined with Methallenestril.Approved
RitonavirThe serum concentration of Methallenestril can be decreased when it is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Methallenestril can be decreased when it is combined with Rivaroxaban.Approved
RofecoxibRofecoxib may increase the thrombogenic activities of Methallenestril.Investigational, Withdrawn
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Methallenestril.Approved, Investigational
S-3304The serum concentration of Methallenestril can be decreased when it is combined with S-3304.Investigational
SaquinavirThe serum concentration of Methallenestril can be decreased when it is combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Methallenestril can be decreased when it is combined with Saxagliptin.Approved
SecobarbitalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Methallenestril.Approved, Investigational, Vet Approved
SimeprevirThe serum concentration of Methallenestril can be decreased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Methallenestril can be decreased when it is combined with Sitagliptin.Approved, Investigational
SivelestatThe serum concentration of Methallenestril can be decreased when it is combined with Sivelestat.Investigational
SomatotropinThe therapeutic efficacy of Somatotropin can be decreased when used in combination with Methallenestril.Approved, Investigational
SpiraprilThe serum concentration of Methallenestril can be decreased when it is combined with Spirapril.Approved
St. John's WortThe therapeutic efficacy of Methallenestril can be decreased when used in combination with St. John's Wort.Investigational, Nutraceutical
SulodexideMethallenestril may decrease the anticoagulant activities of Sulodexide.Approved, Investigational
TelaprevirThe serum concentration of Methallenestril can be decreased when it is combined with Telaprevir.Approved, Withdrawn
TemocaprilThe serum concentration of Methallenestril can be decreased when it is combined with Temocapril.Experimental, Investigational
ThalidomideMethallenestril may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Methallenestril can be decreased when it is combined with Thiorphan.Experimental
TioclomarolMethallenestril may decrease the anticoagulant activities of Tioclomarol.Experimental
TipranavirMethallenestril may increase the dermatologic adverse activities of Tipranavir.Approved, Investigational
TixocortolThe serum concentration of Tixocortol can be increased when it is combined with Methallenestril.Approved, Withdrawn
TopiramateThe serum concentration of Methallenestril can be decreased when it is combined with Topiramate.Approved
TrandolaprilThe serum concentration of Methallenestril can be decreased when it is combined with Trandolapril.Approved
Tranexamic AcidMethallenestril may increase the thrombogenic activities of Tranexamic Acid.Approved
TretinoinThe therapeutic efficacy of Methallenestril can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be increased when it is combined with Methallenestril.Approved, Vet Approved
TroxerutinMethallenestril may decrease the anticoagulant activities of Troxerutin.Investigational
UbenimexThe serum concentration of Methallenestril can be decreased when it is combined with Ubenimex.Experimental, Investigational
UlinastatinThe serum concentration of Methallenestril can be decreased when it is combined with Ulinastatin.Investigational
UlobetasolThe serum concentration of Ulobetasol can be increased when it is combined with Methallenestril.Approved
Ursodeoxycholic acidThe therapeutic efficacy of Ursodeoxycholic acid can be decreased when used in combination with Methallenestril.Approved, Investigational
ValdecoxibValdecoxib may increase the thrombogenic activities of Methallenestril.Investigational, Withdrawn
VildagliptinThe serum concentration of Methallenestril can be decreased when it is combined with Vildagliptin.Approved, Investigational
Vitamin CThe serum concentration of Methallenestril can be increased when it is combined with Vitamin C.Approved, Nutraceutical
VoriconazoleThe metabolism of Methallenestril can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinMethallenestril may decrease the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Methallenestril can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
Z-Val-Ala-Asp fluoromethyl ketoneThe serum concentration of Methallenestril can be decreased when it is combined with Z-Val-Ala-Asp fluoromethyl ketone.Experimental
ZofenoprilThe serum concentration of Methallenestril can be decreased when it is combined with Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
59084697
PubChem Substance
347829260
ChemSpider
34995295
Wikipedia
Methallenestril
ATC Codes
G03CC03 — MethallenestrilG03CB03 — Methallenestril

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00102 mg/mLALOGPS
logP4.69ALOGPS
logP4.72ChemAxon
logS-5.4ALOGPS
pKa (Strongest Acidic)4.53ChemAxon
pKa (Strongest Basic)-4.8ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity83.11 m3·mol-1ChemAxon
Polarizability32.23 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as naphthalenes. These are compounds containing a naphthalene moiety, which consists of two fused benzene rings.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Naphthalenes
Sub Class
Not Available
Direct Parent
Naphthalenes
Alternative Parents
Anisoles / Alkyl aryl ethers / Monocarboxylic acids and derivatives / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Naphthalene / Phenol ether / Anisole / Alkyl aryl ether / Monocarboxylic acid or derivatives / Ether / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide
Molecular Framework
Aromatic homopolycyclic compounds
External Descriptors
Not Available

Drug created on November 04, 2016 15:36 / Updated on December 01, 2017 16:37